Navigation Links
Elsevier's Biochimica et Biophysica Acta (BBA) Journal Series Adds Open Access Journal: BBA Clinical to its Portfolio
Date:11/13/2013

OXFORD, England, November 13, 2013 /PRNewswire/ --

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of BBA Clinical, the first full open access journal within the Biochimica et Biophysica Acta (BBA) journal series. BBA Clinical will focus on translating molecular insights into clinical research.

BBA Clinical is a biomedical journal dedicated to publishing research on the molecular basis of human diseases, as well as presenting findings from clinical trials that target biochemical pathways and processes. All articles in BBA Clinical describe, in part or entirely, studies using human patient samples or human cohorts. Clinical areas of particular interest include aging, cancer, cardiovascular-, metabolic-, neurological-, and immunological diseases; the interactions that may occur among these different diseases and conditions; and studies that examine their early or pre-symptomatic states. Cross-sectional and prospective studies from well-established cohorts, and studies involving imaging methodologies, are particularly encouraged for submission.

"The journal provides a new forum for insights concerning the biochemical mechanisms related to diagnosis, progression, and treatment of a wide range of human diseases," said BBA Clinical Executive Editor, Jeffrey N. Keller from Pennington Biomedical Research Center, Baton Rouge, Louisiana. "BBA Clinical will offer not just a useful forum for clinical research today, but it is designed to be a prominent contributor to the larger overall body of clinical advancements far into the future."

"We are very excited about the launch of BBA Clinical," added Dolors Alsina, Executive Publisher at Elsevier. "The journal will build on our long standing track record as one of the leading international journals focusing on molecular aspects in biology and medicine and will break new ground as the clinical complement to BBA Molecular Basis of Disease."

For more information or to submit an article, go to http://www.journals.elsevier.com/bba-clinical

About Open Access Publishing at Elsevier

Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish open access in over 1,600 established peer-reviewed journals as well as 67 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.elsevier.com/openaccess

About Elsevier's Biochimica et Biophysica Acta (BBA) journal portfolio

BBA began publication in 1947. It was the first international journal dedicated to the publication of new findings from the emerging and synergistic fields of biochemistry and biophysics. Since that time, BBA has expanded to meet the needs of scientists focused on understanding the physics, molecular mechanisms, and biomedical underpinnings in diverse fields, including bioenergetics, proteomics, and lipid biology. Today BBA comprises ten different journals, each with unique editors and scope and an average impact factor above 5. The members of the American Library Association recognized BBA's outstanding value in 2009 by electing BBA to the 100 Most Influential Journals in Biology & Medicine over the last 100 years. http://www.elsevier.com/life-sciences/bba

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact

Kristian Wilson
Elsevier
+44-186-584-3817
k.wilson@elsevier.com

 


'/>"/>
SOURCE Elsevier
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier Launches New Open Access Journal: Photoacoustics
2. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
3. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
4. Novation Supplier Diversity Program Recognized in "Best of the Best 2013" by Black EOE Journal
5. Case Report on 14-Year-Old Pediatric Patient Bridged to Transplant with SynCardia Total Artificial Heart Published in the Journal Perfusion
6. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
7. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
8. Elsevier Launches New Open Access Journal in Biomedicine: Journal of Clinical and Translational Endocrinology
9. The Journal of Allergy and Clinical Immunology pubblica i dati sulla termoplastica bronchiale che dimostrano una riduzione sostenuta degli attacchi gravi di asma nellarco di cinque anni
10. Health Decisions CEO Michael Rosenberg, MD, MPH, Offers Insights into Adaptive and Risk-Based Monitoring in the Journal of Clinical Research Best Practices
11. AVTs Customer Medbox, Makes Wall Street Journal MarketWatch Headlines Again
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):